这笔交易总额约为41,542美元。出售后，Grasso仍保留公司330,651股股份的所有权。此次出售是为了满足与限制性股票单位归属相关的税务义务。尽管公司保持着3.29的强劲流动比率，且资产负债表上现金多于债务， InvestingPro ...

根据最近向美国证券交易委员会提交的文件显示，Alector, Inc. (NASDAQ:ALEC)的首席医疗官Gary Romano出售了14,892股普通股。此次交易发生之际，该公司股票价格接近52周低点2.37美元，过去六个月内已下跌超过50%。根据 InvestingPro 分析，基于公允价值指标，该股票目前似乎被低估。这些股票于2024年12月2日以平均价格2.5194美元售出，总交易价值 ...

Vigil Neuroscience's stock dropped after Alector's AL002 failed in Alzheimer's, raising concerns about VG-3927's efficacy.

根据Alector发布的最新财务报告，公司的营业收入为1534万美元，而净利润则显示出公司面临严重亏损，达到了4222万美元，每股收益为-0.43美元。这样的业绩在生物技术行业中并不罕见，尤其是处于研发阶段的公司，但仍然可能令投资者对于未来的盈利能力产生质疑。此外，该公司目前的毛利为1315万美元，市盈率为-1.44倍，这一数据表明，市场对其未来盈利的预期相对负面。

北京时间2024年12月03日02时39分，Alector, Inc.（ALEC.us）股票出现波动，股价急速跳水5.02%。截至发稿，该股报2.46美元/股，成交量144.382万股， 换手率 1.47%，振幅6.53%。

On Friday, Alector Inc (ALEC) stock saw a modest uptick, ending the day at $2.6 which represents a slight increase of $0.05 or 1.96% from the prior close of $2.55. The stock opened at $2.55 and ...

Alector (NASDAQ:ALEC – Free Report) had its price target reduced by HC Wainwright from $35.00 to $7.00 in a report published on Friday, MarketBeat.com reports. They currently have a buy rating on the ...

On Wednesday, Alector Inc (ALEC) stock saw a decline, ending the day at $2.55 which represents a decrease of $-0.02 or -0.78% from the prior close of $2.57. The stock opened at $2.6 and touched a low ...

Cantor Fitzgerald reiterated their overweight rating on shares of Alector (NASDAQ:ALEC – Free Report) in a research report ...

Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...

Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.

US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...